Edinburgh, UK, 22nd June 2016 / Synpromics Ltd, the leading synthetic promoter company, is pleased to announce an extension to the original collaboration with uniQure announced in January 2015, which focus
Synpromics appoints Dr John Shields as Investor Director and Dr Ken Macnamara as Director of Operations.
Synpromics Ltd, a leading synthetic biology company, and The Cell Therapy Catapult announce the launch of a collaboration to remove a major barrier to the development of the cell and gene therapy.
Synthetic promoters to be developed for gene therapy in eye disease.
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, and Synpromics Limited, a leading synthetic promoter development company backed by Calculus Capital, today announced they have entered into a broad, multi-target collaboration agreement.